好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The Risk of Epilepsy in Systemic Autoimmune Diseases: A Population-based Study in Olmsted County, Minnesota
Autoimmune Neurology
P2 - Poster Session 2 (2:45 PM-3:45 PM)
044

Determine the risk and etiology of epilepsy among systemic autoimmune conditions including rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). 

Population-based epidemiology studies evaluating a link between epilepsy and systemic autoimmune diseases are lacking.

Using the Rochester Epidemiology Project medical records-linkage system, we identified incident cases matched to comparators by age and sex within Olmsted County, Minnesota of RA from 1980-2013, and SLE from 1976-2018. We reviewed the records to identify seizures and their etiologies following the incidence of RA or SLE. Cox models were used to compare development of epilepsy by RA status, adjusted for age, sex and index year.  

Among the 1063 identified RA patients and 1063 comparators, 27 cases and 13 comparators developed seizures following the index date with a hazard ratio of 2.33 (95% CI 1.20-4.53). Most common seizure etiology for RA cases was stroke (9/27, 33%). None of the patients had autoimmune encephalitis. Among RA patients with seizures, 26/27 (96%) developed long-term epilepsy. EEG was abnormal in 14/23 (61%) RA patients, but only nine demonstrated epileptiform discharges. Among the 188 SLE patients and 188 comparators, five SLE patients and three comparators developed seizures following the index date. A hazard ratio was not calculated due to the small number of patients with seizures. Only one of the five SLE patients with seizures had features of seronegative probable autoimmune encephalitis. Among those with seizures, 3/5 (60%) SLE patients developed long-term epilepsy. EEG was abnormal in 3/3 (100%) cases and two had focal epileptiform discharges. 

RA was associated with an increased risk of epilepsy, mostly secondary to comorbidities. Epilepsy frequency among the SLE population was not high enough to significantly suggest a relationship. Seizure secondary to autoimmune encephalitis was not a common cause of seizures among these populations.

Authors/Disclosures
Shemonti Hasan, MD
PRESENTER
Dr. Hasan has nothing to disclose.
Adam Nguyen No disclosure on file
Sara Achenbach No disclosure on file
Hannah Langenfeld No disclosure on file
Michelle Devine, MD (Olmsted Medical Center) The institution of an immediate family member of Dr. Devine has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. The institution of an immediate family member of Dr. Devine has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Astellas. An immediate family member of Dr. Devine has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. An immediate family member of Dr. Devine has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for AAN. An immediate family member of Dr. Devine has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for AGRIMS. An immediate family member of Dr. Devine has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Advances in Neurology. The institution of an immediate family member of Dr. Devine has received research support from Center of Individualized Medicine, Mayo Clinic.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Merck. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology that is relevant to AAN interests or activities.
Cynthia Crowson (Mayo Clinic) Cynthia Crowson has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Rheumatology.
Divyanshu Dubey, MD, FAAN (Mayo Clinic) The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Argenx. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys. The institution of Dr. Dubey has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from Department of Defense . Dr. Dubey has received research support from UCB. Dr. Dubey has received research support from David J. Tomassoni ALS Research Grant Program . Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care. Dr. Dubey has received intellectual property interests from a discovery or technology relating to health care.